Comparison of Efficacy of Intravitreal Ranibizumab Between Non-vitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: 2-year Results



To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy.

Materials & Methods:

We retrospectively assessed the best-corrected visual acuity (BCVA), central macular thickness (CMT) and total macular volume (TMV) at baseline, 6,12,18 and 24 months of the follow up. The number of IVL, duration of DM and HbA1C at baseline were also assessed.


There was no significant difference in the baseline BCVA, CMT, TMV and total IVR number between both groups. In the vitrectomized group (n = 13), the BCVA, CMT and TMV were significantly different from baseline only on 18th and 24th month visits, whereas in the control group (n=17) there was improvement in all parameters in all the visits. When two groups were compared, BCVA and the number of IVR were significantly higher on month 6 in the control group and that was probably due to the loading dose which was applied to the control group patients in the first three months. The difference between the other parameters on all the other visits was not significant.


IVR is an effective treatment for DME in vitrectomized eyes. Although the response was slower when compared to non vitrectomized patients, on the 24 month the BCVA was equal in both groups.


Aylin Ardagil Akçakaya
Istanbul, Turkey
Email :
Cell Phone: +905327853380
Work Phone: +902165664000